|
 |
 |
|
|
|
| Friday, 30 September 2005 10:35 | | BNN: British Nursing News Online · www.bnn-online.co.uk
|
|
|
The Medicines and Healthcare Regulatory Agency has warned that a drug taken by 15,000 children in the UK to treat attention deficit and hyperactivity disorder has been found to increase the risk of suicidal thoughts.
The MHRA said yesterday that it would now re-examine the benefits of Strattera, which is manufactured by Lilly.
The warning follows findings announced earlier this week that the risk of suicide is increased among children using antidepressants called Selective Serotonin Re-uptake Inhibitors.
June Raine, the director of medicines post-licensing at the MHRA, said: "We are advising healthcare professionals that patients should be carefully monitored for signs of depression, suicidal thoughts or suicidal behaviour and referred for alternative treatment if necessary.
"Children who are doing well on the medication should continue their treatment. Those who experience any unusual symptoms, or are concerned, should speak to their doctor to discuss the best course of action."
In response, Lilly said there had been six reports of suicidal thoughts out of 1,357 patients – a rate of 0.44 per cent – and no suicides.
It added that Strattera was the most widely used an stringently tested of all ADHD medicines.
|
|
| -
0 comments on this story
|
|
|
Home Top Disclaimer Site
Credits
Nursing Jobs | Just for Nurses | Nursing Agencies List | Charles Bloe Training
Nursing Portal | Nursing Events | Brutish Nursing | British Nursing Websites
Website Development and SEO Services
|
|
|
